PMID- 32904832
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2364-3722 (Print)
IS  - 2196-9736 (Electronic)
IS  - 2196-9736 (Linking)
VI  - 8
IP  - 9
DP  - 2020 Sep
TI  - Single-center experience demonstrating low adverse events and high efficacy with 
      self-expandable metal esophageal and biliary stents for pseudocyst and walled off 
      necrosis drainage.
PG  - E1156-E1160
LID - 10.1055/a-1178-0185 [doi]
AB  - Background and study aims  Lumen-apposing metal stents (LAMS) have been designed 
      as proprietary stents for the management of pseudocysts (PC)/walled off necrosis 
      (WON). There has been concern about adverse events (AEs) with LAMS including 
      bleeding, buried stent syndrome and migration. Prior to LAMS becoming available, 
      fully-covered self-expandable metal esophageal and biliary stents (FCSEMSs) were 
      used off-label for management of PC/WON with many centers demonstrating low rates 
      of AEs. The primary aim of this study was to study the safety and efficacy of 
      FCSEMS for the management of pseudocysts/WON. Patients and methods  This was a 
      retrospective review of all endoscopic ultrasound (EUS)-guided placement of 
      FCSEMSs for drainage of PC/WON cases performed at our institution over 4-year 
      period. The primary outcomes studied were technical success, AEs, PC/WON 
      resolution, and salvage surgical/radiologic intervention. Results  Technical 
      success achieved in 65 of 65 (100 %) study patients. An AE occurred 0 of 25 
      patients (0 %) with PC, and in 10 of 40 patients (25 %) with WON: bleeding (3 %), 
      migration (5 %) and stent dysfunction/infection (18 %). There was resolution in 
      25 of 25 patients (100 %) with a PC and 31 of 40 patients (78 %) with a WON. 
      Salvage therapy by interventional radiology or surgery was performed in nine of 
      40 patients (22 %). Conclusions  This single-center 4-year experience in the 
      pre-LAMS era showed that FCSEMS was safe and effective in all patients with PC 
      and over 75 % of patients with WON. Given the large cost differential between 
      LAMS and FCSEMS and the efficacy and safety shown with FCSEMS, we believe that 
      FCSEMS should still be considered a first-line option for patients with 
      pancreatic fluid collections, particularly in patients with PCs.
FAU - Ortizo, Ronald Dungca
AU  - Ortizo RD
AD  - H. H. Chao Comprehensive Digestive Disease Center, University of California, 
      Irvine Medical Center, Orange, California, United States.
FAU - Jalali, Farid
AU  - Jalali F
AD  - H. H. Chao Comprehensive Digestive Disease Center, University of California, 
      Irvine Medical Center, Orange, California, United States.
FAU - Thieu, Daniel
AU  - Thieu D
AD  - H. H. Chao Comprehensive Digestive Disease Center, University of California, 
      Irvine Medical Center, Orange, California, United States.
FAU - Yu, Allen
AU  - Yu A
AD  - H. H. Chao Comprehensive Digestive Disease Center, University of California, 
      Irvine Medical Center, Orange, California, United States.
FAU - Bucayu, Robert
AU  - Bucayu R
AD  - H. H. Chao Comprehensive Digestive Disease Center, University of California, 
      Irvine Medical Center, Orange, California, United States.
FAU - Paiji, Christopher
AU  - Paiji C
AD  - H. H. Chao Comprehensive Digestive Disease Center, University of California, 
      Irvine Medical Center, Orange, California, United States.
FAU - Fortinsky, Kyle
AU  - Fortinsky K
AD  - H. H. Chao Comprehensive Digestive Disease Center, University of California, 
      Irvine Medical Center, Orange, California, United States.
FAU - Chang, Kenneth
AU  - Chang K
AD  - H. H. Chao Comprehensive Digestive Disease Center, University of California, 
      Irvine Medical Center, Orange, California, United States.
FAU - Lee, John Gunn
AU  - Lee JG
AD  - H. H. Chao Comprehensive Digestive Disease Center, University of California, 
      Irvine Medical Center, Orange, California, United States.
FAU - Samarasena, Jason Buddika
AU  - Samarasena JB
AD  - H. H. Chao Comprehensive Digestive Disease Center, University of California, 
      Irvine Medical Center, Orange, California, United States.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - Germany
TA  - Endosc Int Open
JT  - Endoscopy international open
JID - 101639919
PMC - PMC7458734
COIS- Competing interests J. Samarasena - Consultant: Medtronic, Olympus, Conmed, 
      Neptune medical, Motus, Pentax, Mauna Kea Technologies.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
PMCR- 2020/09/01
CRDT- 2020/09/09 18:08
PHST- 2019/02/11 00:00 [received]
PHST- 2019/09/30 00:00 [accepted]
PHST- 2020/09/09 18:08 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - 10.1055/a-1178-0185 [doi]
PST - ppublish
SO  - Endosc Int Open. 2020 Sep;8(9):E1156-E1160. doi: 10.1055/a-1178-0185. Epub 2020 
      Aug 31.